Hypoglycemia (when combined) on Mounjaro (tirzepatide for T2D): Incidence, Severity, and Realistic Expectations
Evidence-anchored overview of hypoglycemia risk when Mounjaro (tirzepatide) is combined with insulin or sulfonylureas: what the SURPASS trial program supports, what needs primary-source verification, who is most at risk, and what to do right now.

